Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Giredestrant versus fulvestrant plus investigator's choice CDK4/6 inhibitor in endocrine-resistant ER-positive, HER2-negative advanced breast cancer
MOH_2024-01-08_013132Phase 3Recruiting
- Sponsor
- Roche
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of giredestrant, fulvestrant, palbociclib, ribociclib and abemaciclib in breast cancer (2 arms), sponsored by Roche. Started Dec 2023; status: recruiting.
02
Drugs
giredestrantfulvestrantpalbociclibribociclibabemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2024-01-08_013132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-01-08_013132.